ScholarLens Back to search
2011•Practical Journal of Clinical MedicineRequires access

Effect of Bortezomib on serum cystatin-C in multiple myeloma

Rong Xiao

Open publisher page 0 citations

Abstract

Objective The aim of this study was to assess the effect of Bortezomib on serum cystatin-C(Cys-C)in multiple myeloma and whether Cys-C can monitor tumor load.Methods We measured serum Cys-C and β2-microglobulin in multiple myeloma patients and 20 healthy controls pre-and post-Bortezomib therapy.Results Multiple myeloma patients had higher Cys-C and β2-microglobulin levels compared with healthy controls(P0.05).Treatment with Bortezomib produced a significant reduction of cystatin-C and β2-microglobulin,mainly in relapsed patients(P0.05).Conclusion Treatment with Bortezomib can significantly reduce the Cys-C levels,which can be regarded as the potential indicator to monitor tumor load,and β2-microglobulin levels of multiple myeloma patients.

About this research paper

What this paper is about

Objective The aim of this study was to assess the effect of Bortezomib on serum cystatin-C(Cys-C)in multiple myeloma and whether Cys-C can monitor tumor load.Methods We measured serum Cys-C and β2-microglobulin in multiple myeloma patients and 20 healthy controls pre-and post-Bortezomib therapy.Results Multiple myeloma patients had higher Cys-C and β2-microglobulin levels compared with healthy controls(P0.05).Treatment with Bortezomib produced a significant reduction of cystatin-C and β2-microglobulin,mainly in relapsed patients(P0.05).Conclusion Treatment with Bortezomib can significantly reduce the Cys-C levels,which can be regarded as the potential indicator to monitor tumor load,and β2-microglobulin levels of multiple myeloma patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective The aim of this study was to assess the effect of Bortezomib on serum cystatin-C(Cys-C)in multiple myeloma and whether Cys-C can monitor tumor load.Methods We measured serum Cys-C and β2-microglobulin in multiple myeloma patients and 20 healthy controls pre-and post-Bortezomib therapy.Results Multiple myeloma patients had higher Cys-C and β2-microglobulin levels compared with healthy controls(P0.05).Treatment with Bortezomib produced a significant reduction of cystatin-C and β2-microglobulin,mainly in relapsed patients(P0.05).Conclusion Treatment with Bortezomib can significantly reduce the Cys-C levels,which can be regarded as the potential indicator to monitor tumor load,and β2-microglobulin levels of multiple myeloma patients.

Key concepts: Bortezomib, Multiple myeloma, Medicine, Beta-2 microglobulin, Cystatin, Internal medicine, Myeloma protein, Cystatin C

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Effect of Bortezomib on serum cystatin-C in multiple myeloma — Research Paper | ScholarLens